Physician profile
Deepak Raheja
NPI 1548281413
$1,942.57
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $655 · 2021: $166 · 2022: $23.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $301.85 | 2019-2022 | |
| Allergan, INC. | $212.79 | 2020 | |
| Lilly USA, LLC | $188.93 | 2019-2021 | |
| Ucb, INC. | $148.13 | 2019 | |
| Sunovion Pharmaceuticals INC. | $133.34 | 2019-2020 | |
| Horizon Therapeutics Plc | $107.93 | 2019 | |
| Sk Life Science, INC. | $101.07 | 2020-2021 | |
| Amgen INC. | $88.67 | 2019 | |
| Zyla Life Sciences, INC. | $80.78 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $72.19 | 2019-2020 | |
| Janssen Biotech, INC. | $53.85 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $52.94 | 2020-2021 | |
| Eisai INC. | $51.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.14 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $42.02 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $35.78 | 2019 | |
| Mallinckrodt Enterprises LLC | $34.53 | 2019 | |
| Genzyme Corporation | $34.08 | 2019 | |
| Tanabe Pharma America, INC. | $30.85 | 2019 | |
| Shire North American Group INC | $23.32 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.22 | 2020 | |
| Supernus Pharmaceuticals, INC. | $17.35 | 2020 | |
| Abbvie INC. | $17.29 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.33 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.00 | 2020 | |
| Assertio Therapeutics, INC. | $13.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4.54 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Raheja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.